Pharmaceuticals
Biologics

Roche to present divarasib, giredestrant and Tam-Peli data at ESMO 2026

Roche heads to ESMO 2026 with Phase III readouts across KRAS G12C lung cancer, early breast cancer and a next-generation B7-H3 ADC.
Roche heads to ESMO 2026 with Phase III readouts across KRAS G12C lung cancer, early breast cancer and a next-generation B7-H3 ADC.
The Biotech Times Editorial Team  · 
Pharmaceuticals

Eikon Therapeutics to present seven abstracts at ESMO 2026

Eikon will share clinical updates across four oncology candidates, including EIK1001 in NSCLC and two PARP1 inhibitors, at ESMO Congress in Madrid.
Eikon will share clinical updates across four oncology candidates, including EIK1001 in NSCLC and two PARP1 inhibitors, at ESMO Congress in Madrid.
The Biotech Times Editorial Team  · 
Medical Devices
Pharmaceuticals
Diagnostics

IBA launches NEPTIS Perform Duo for tracer development and production

IBA's first product from its ORA acquisition unifies PET tracer development and routine manufacturing on a single synthesizer module.
IBA's first product from its ORA acquisition unifies PET tracer development and routine manufacturing on a single synthesizer module.
The Biotech Times Editorial Team  · 
Diagnostics
Digital Health
Medical Devices

EXIT-CVD consortium launches 22 clinical studies across Europe

The 42-partner, EUR 27.6m consortium led by Philips and UMCG will enrol 14,000+ patients across 17 countries to reshape cardiovascular care.
The 42-partner, EUR 27.6m consortium led by Philips and UMCG will enrol 14,000+ patients across 17 countries to reshape cardiovascular care.
The Biotech Times Editorial Team  · 
Digital Health
Bioinformatics
Diagnostics

Neumarker and Cortica partner to develop AI biomarkers for autism

The two US companies will combine Neumarker's EEG foundation model with Cortica's longitudinal clinical data to identify biomarkers predicting treatment response in
The two US companies will combine Neumarker's EEG foundation model with Cortica's longitudinal clinical data to identify biomarkers predicting treatment response in
The Biotech Times Editorial Team  · 
Biologics
Pharmaceuticals

Tiziana completes Phase 2 enrolment for foralumab in Alzheimer's

Tiziana Life Sciences has dosed the last patient in its Phase 2 trial of intranasal foralumab for mild Alzheimer's, with topline data expected in
Tiziana Life Sciences has dosed the last patient in its Phase 2 trial of intranasal foralumab for mild Alzheimer's, with topline data expected in
The Biotech Times Editorial Team  · 
Pharmaceuticals
Biologics

InnoCare orelabrutinib data presented in three JSH 2026 oral sessions

InnoCare Pharma shared real-world CLL/SLL and Phase 2 data for its BTK inhibitor orelabrutinib across three oral presentations at the Japanese Society of
InnoCare Pharma shared real-world CLL/SLL and Phase 2 data for its BTK inhibitor orelabrutinib across three oral presentations at the Japanese Society of
The Biotech Times Editorial Team  · 
Diagnostics
Genomics

MDxHealth suspends 2026 guidance after sales force disruption

The urology diagnostics company reported flat Q3 revenue of $22.7m and withdrew its $110–115m full-year target following unexpected sales team attrition.
The urology diagnostics company reported flat Q3 revenue of $22.7m and withdrew its $110–115m full-year target following unexpected sales team attrition.
The Biotech Times Editorial Team  · 
Medical Devices
Regulatory Science

Femasys doubles FINALE trial sites to twelve for FemBloc device

Femasys has expanded its US pivotal trial network to twelve sites, adding Baylor and Columbia, as it pursues FDA approval for its non-surgical birth
Femasys has expanded its US pivotal trial network to twelve sites, adding Baylor and Columbia, as it pursues FDA approval for its non-surgical birth
The Biotech Times Editorial Team  · 
Pharmaceuticals
Diagnostics
Bioinformatics

Recursion raises $200m, reports FAP and cancer trial updates

The AI-driven drug discovery company also disclosed a Sanofi option milestone and extended its cash runway into 2029.
The AI-driven drug discovery company also disclosed a Sanofi option milestone and extended its cash runway into 2029.
The Biotech Times Editorial Team  · 
Pharmaceuticals
Genomics
Bioinformatics

Microbiotica raises £36m Series C to fund Phase 2 UC trial of MB310

The Cambridge microbiome biotech closed its Series C, led by British Business Bank, to advance oral candidate MB310 into a Phase 2 ulcerative colitis study.
The Cambridge microbiome biotech closed its Series C, led by British Business Bank, to advance oral candidate MB310 into a Phase 2 ulcerative colitis study.
The Biotech Times Editorial Team  · 
Pharmaceuticals
Biologics
Regulatory Science

Ascendis Pharma's navepegritide wins CHMP backing for achondroplasia

The EMA advisory committee has recommended EU marketing authorisation for TransCon CNP in children aged two and over, with an EC decision expected before year
The EMA advisory committee has recommended EU marketing authorisation for TransCon CNP in children aged two and over, with an EC decision expected before year
The Biotech Times Editorial Team  · 
Subscribe to